Liver and Bile

Hepatology. 2023;77(5):1746–56

Huang DQ, Tamaki N, Lee HW, Park SY, Lee YR, Lee HW, Lim SG, Lim TS, Kurosaki M, Marusawa H, Mashiba T, Kondo M, Uchida Y, Kobashi H, Furuta K, Izumi N, Kim BK, Sinn DH

Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV DNA in compensated cirrhosis


Background: Comparative outcomes of hepatitis B virus (HBV)-infected compensated cirrhosis with low-level viremia (LLV) versus maintained virological response (MVR) are unclear. A large, multiethnic, multicenter study was conducted to examine the natural history of LLV versus MVR in compensated cirrhosis. Patients and methods: The authors enrolled patients with HBV-infected compensated cirrhosis (n = 2316) from 19 hospitals in South Korea, Singapore, and Japan. They defined the LLV group as untreated patients with ≥ 1 detectable serum HBV DNA (20–2000 IU/ml), Spontane-ous-MVR group as untreated patients with spontaneously achieved MVR, and antiviral therapy (AVT)-MVR group as patients achieving AVT-induced MVR. Study end points were hepatocellular carcinoma (HCC) or hepatic decompensation.
Results: The annual HCC incidence was 2.7 per 100 person-years (PYs), 2.6 per 100 PYs, and 3.3 per 100 PYs for LLV (n = 742), Spontaneous-MVR (n = 333), and AVT-MVR (n = 1241) groups, respectively (p = 0.81 between LLV vs. Spontaneous-MVR groups and p = 0.37 between LLV vs. AVT-MVR groups). Similarly, the annual decompensation incidence was 1.6 per 100 PYs, 1.9 per 100 PYs, and 1.6 per 100 PYs for LLV, Sponta-neous-MVR, and AVT-MVR groups, respectively (p = 0.40 between LLV vs. Spontaneous-MVR groups and p = 0.83 between LLV vs. AVT-MVR groups). Multivariable analyses determined that HCC and decompensation risks in the LLV group were comparable to those with Spontane-ous-MVR and AVT-MVR groups (all p > 0.05). Propensity score matching also reproduced similar results for HCC and decompensation risks (all p > 0.05 between LLV vs. Spontaneous-MVR groups and between LLV vs. AVT-MVR groups).

Conclusions: Untreated low-level viremia in hepatitis B virus-infected compensated cirrhosis is not associated with increased risk of disease pro-gression compared with Spontaneous-MVR and AVT-MVR. These data have important implications for practice and further research.

Dr. Dr. B.K. Kim, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea,
E-Mail: beomkkim@yuhs.ac

or

Dr. Dr. D.H. Sinn, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea,
E-Mail: dh.sinn@samsung.com

DOI: 10.1097/hep.0000000000000037

Back to overview

this could be of interest:

Acute severe non-A-E-hepatitis of unknown origin in children – A 30-year retrospective observational study from North-West Germany

J Hepatol. 2023;78(5):971–8

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated

J Hepatol. 2023;78(5):989–97

More articles on the topic